Key Highlights
- MGRX shares climbed more than 129% Monday following an SEC disclosure showing CEO Jacob Cohen acquired 500,000 bonus shares.
- Cohen transferred an additional 200,000 shares into The Tiger Cub Trust under his control, elevating the trust’s holdings to 805,000 shares.
- Daily trading volume surged past 107 million shares, dramatically exceeding the three-month average of approximately 208,000.
- Friday’s session had seen the stock decline 54.51%, with year-to-date losses reaching 78.11%.
- Analyst consensus positions the stock at “Strong Sell” with zero active price targets currently published.
Mangoceuticals (MGRX) shares experienced a dramatic rise exceeding 129% during Monday’s trading session following the emergence of an SEC filing detailing CEO Jacob Cohen’s receipt of 500,000 shares through his bonus compensation structure.
The same regulatory filing documented Cohen’s movement of 200,000 shares into The Tiger Cub Trust, an entity under his direct control, which increased the trust’s aggregate position to 805,000 shares. The simultaneous appearance of both transactions in a single filing generated considerable attention among market participants.
Friday’s preceding session had witnessed a 54.51% decline in share price. The stock maintains substantial losses of 78.11% for the current year and 96.59% across the trailing 12-month period.
Monday’s extraordinary trading activity pushed share volume beyond 107 million. This represents a massive expansion compared to the stock’s typical three-month daily average volume of roughly 208,000 shares.
According to MarketBeat information, the stock last recorded a closing price near $2.33 per share in late October 2025. Currently, no Wall Street analysts have published active price targets for the security.
Legal Action and Patent Filings
The company has pursued multiple strategic initiatives beyond insider share transactions. Mangoceuticals announced the filing of a civil legal action against Clarity Ventures, Inc., its former technology services provider, pursuing damages that exceed $73 million. The complaint centers on alleged shortcomings in technology delivery and platform construction.
Regarding intellectual property expansion, Mangoceuticals submitted a PCT international patent application during February covering MGX-0024, an antiviral additive formulation designed for incorporation into animal feed and water systems. The filing date of February 26, 2026, initiates the process for securing worldwide patent coverage.
Operational Updates
The company’s testosterone replacement therapy (TRT) injectable subscription service, available at $99 monthly, has shown encouraging performance metrics. Company leadership highlighted 336% month-over-month revenue expansion since mid-December alongside a 54% reduction in costs associated with acquiring new customers.
Mangoceuticals launched MangoRx Direct and PeachesRx Direct in November 2025. These digital health platforms enable patient access to GLP-1 weight management medications including Zepbound and Wegovy, with monthly pricing beginning around $499 through direct cash payment arrangements.
Analyst coverage remains limited, with MarketBeat reporting one Sell rating while Buy and Hold recommendations remain absent from published research.
The prevailing Wall Street consensus categorizes the stock as “Strong Sell,” with no major financial institutions having released rating changes, upgrades, downgrades, or fresh price objectives during recent reporting periods.
Available records show the most recent documented closing price at approximately $2.33 per share from late October 2025.
